Abstract
Polypeptides and proteins may undergo misfolding processes resulting in aggregates: oligomers and fibrils possessing toxic properties. In most cases a beta-structure will be formed with high tendency to form suprachemical structures, assemblies. The aggregation grade might play crucial role in the biological activities of protein assemblies. Protein aggregates bind to receptors or receptor complexes of neuronal and glial cells and activate signal transduction pathways. Beta amyloid may interact with Wnt receptors as well as increases the intracellular Ca-ion level in neurons. GSK-3beta activation causes tau-hyperphosphorylation and collaps of the microtubular system. β-amyloid triggers also a CD36 dependent signaling cascade and activates microglia. Other misfolded protein assemblies of alpha-synuclein, huntingtin and prion proteins similarly interact with receptor complexes and disturb signal transduction. Rational drug design may start after understanding these signalisation disturbances. Novel drugs will prevent receptor interaction with misfolded protein aggregates.
Keywords: Misfolded protein, beta-amyloid, receptor mediation, signal transduction, neurodegenerative disorders
Current Signal Transduction Therapy
Title: Polypeptide and Protein Aggregates with Neurotoxic Properties in Neurodegenerative Disorders: Emphasis on β-Amyloid-Induced Dysfunction of Receptor-Mediated Signal Transduction Pathways
Volume: 1 Issue: 1
Author(s): Yann Verdier and Botond Penke
Affiliation:
Keywords: Misfolded protein, beta-amyloid, receptor mediation, signal transduction, neurodegenerative disorders
Abstract: Polypeptides and proteins may undergo misfolding processes resulting in aggregates: oligomers and fibrils possessing toxic properties. In most cases a beta-structure will be formed with high tendency to form suprachemical structures, assemblies. The aggregation grade might play crucial role in the biological activities of protein assemblies. Protein aggregates bind to receptors or receptor complexes of neuronal and glial cells and activate signal transduction pathways. Beta amyloid may interact with Wnt receptors as well as increases the intracellular Ca-ion level in neurons. GSK-3beta activation causes tau-hyperphosphorylation and collaps of the microtubular system. β-amyloid triggers also a CD36 dependent signaling cascade and activates microglia. Other misfolded protein assemblies of alpha-synuclein, huntingtin and prion proteins similarly interact with receptor complexes and disturb signal transduction. Rational drug design may start after understanding these signalisation disturbances. Novel drugs will prevent receptor interaction with misfolded protein aggregates.
Export Options
About this article
Cite this article as:
Verdier Yann and Penke Botond, Polypeptide and Protein Aggregates with Neurotoxic Properties in Neurodegenerative Disorders: Emphasis on β-Amyloid-Induced Dysfunction of Receptor-Mediated Signal Transduction Pathways, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269208
DOI https://dx.doi.org/10.2174/157436206775269208 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders
Current Medicinal Chemistry Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry Recent Advances and Patents for Nerve Scaffold Biomaterials and their Use for Local, Non-Viral Delivery of Growth Factors and Nucleic Acids
Recent Patents on Biomedical Engineering (Discontinued) Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry RNA Interference: New Therapeutics in Allergic Diseases
Current Gene Therapy Editorial: Current and Emerging Therapeutics in AD
Current Alzheimer Research Ocular Biomarkers of Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Disentangling the Role of the Tau Gene Locus in Sporadic Tauopathies
Current Alzheimer Research Variability in the Effects of Nicotine on Different Regions of the Brain: Changes in the Concentration of Superoxide Dismutase Isoforms
Central Nervous System Agents in Medicinal Chemistry Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9
Letters in Drug Design & Discovery Amyloid-β Immunotherapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets D-Serine Regulation: A Possible Therapeutic Approach for Central Nervous Diseases and Chronic Pain
Mini-Reviews in Medicinal Chemistry An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism Inflammation and Age-Related Iron Accumulation in F344 Rats
Current Aging Science The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry